Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a report released on Friday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Trading Up 1.9 %

ONVO stock opened at $0.76 on Friday. Organovo has a 12-month low of $0.73 and a 12-month high of $2.05. The stock has a market cap of $10.98 million, a price-to-earnings ratio of -0.47 and a beta of 0.68. The business’s 50-day moving average is $0.93 and its 200 day moving average is $1.01.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.